Table 11Low potency statin in combination with ezetimibe as compared to high potency statin monotherapy in general populations: strength of evidence

OutcomeNo. Studies
Risk of BiasDirectnessConsistencyPrecisionReporting Bias

Other Issues
Findings and Magnitude of EffectStrength of Evidence
Long-Term Benefits and Serious Adverse Events
Mortality2aLowNAConsistentImpreciseNot detected

No deaths in any armInsufficient
Acute Coronary EventsNoneNANANANANANo eligible studiesInsufficient
Revascularization ProceduresNoneNANANANANANo eligible studiesInsufficient
Serious Adverse EventsNoneNANANANANANo eligible studiesInsufficient
Surrogate Clinical Outcomes

[LDL not directly measured in all trials]

[six favored combination, three neutral, three monotherapy]
ImpreciseNot detected

Six comparisons favored combination therapy for lowering LDL-c as compared to monotherapy (difference 2 percent to 12 percent), three favored monotherapy, four showed no difference.Low

[HDL directly measured]

[three favored combination, six neutral, one monotherapy]]
ImpreciseNot detected

Three comparisons favored combination therapy for raising HDL-c as compared to monotherapy (difference5.14 percent to 6.3 percent).Low

HDL = high-density lipoprotein; LDL = low-density lipoprotein; NA = not applicable


Missing N in at least one trial.

From: Results

Cover of Combination Therapy Versus Intensification of Statin Monotherapy: An Update
Combination Therapy Versus Intensification of Statin Monotherapy: An Update [Internet].
Comparative Effectiveness Reviews, No. 132.
Monroe AK, Gudzune KA, Sharma R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.